Literature DB >> 12623122

Corticotropin-releasing hormone (CRH) and immunotolerance of the fetus.

Antonis Makrigiannakis1, Emmanuel Zoumakis, Sofia Kalantaridou, Nikos Mitsiades, Andreas Margioris, George P Chrousos, Achilleas Gravanis.   

Abstract

The hypothalamic neuropeptide corticotropin-releasing hormone (CRH) is produced by several tissues of the female reproductive system, including the endometrial glands and decidualized stroma, as well as the trophoblast, syncytiotrophoblast, and placental decidua. CRH is also secreted at inflammatory sites and possesses potent pro-inflammatory properties influencing both innate and acquired immune processes. Recent experimental findings show that uterine CRH participates in local immune phenomena associated with early pregnancy, such as differentiation of endometrial stroma to decidua and protection of the fetus from the maternal immune system. CRH induces the expression of apoptotic Fas ligand (FasL) on invasive extravillous trophoblast and maternal decidual cells at the fetal-maternal interface. Furthermore, CRH increases the apoptosis of activated T lymphocytes through FasL induction, participating in the processes of both implantation and early pregnancy tolerance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623122     DOI: 10.1016/s0006-2952(02)01547-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Low serum secretory immunoglobulin A level and sense of coherence score at an early gestational stage as indicators for subsequent threatened premature birth.

Authors:  Naomi Sekizuka; Akemi Sakai; Keiko Shimada; Noriko Tabuchi; Yukie Kameda; Hiroyuki Nakamura
Journal:  Environ Health Prev Med       Date:  2009-07-07       Impact factor: 3.674

2.  Association between the sense of coherence 13-item version scale score of pregnant women in the second trimester of pregnancy and threatened premature birth.

Authors:  Naomi Sekizuka-Kagami; Keiko Shimada; Noriko Tabuchi; Hiroyuki Nakamura
Journal:  Environ Health Prev Med       Date:  2015-01-14       Impact factor: 3.674

3.  Levels of maternal serum corticotropin-releasing hormone (CRH) at midpregnancy in relation to maternal characteristics.

Authors:  Yumin Chen; Claudia Holzman; Hwan Chung; Patricia Senagore; Nicole M Talge; Theresa Siler-Khodr
Journal:  Psychoneuroendocrinology       Date:  2009-12-16       Impact factor: 4.905

Review 4.  Vital and vulnerable functions of the primate placenta critical for infant health and brain development.

Authors:  Christopher L Coe; Gabriele R Lubach
Journal:  Front Neuroendocrinol       Date:  2014-04-01       Impact factor: 8.606

5.  Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.

Authors:  Ariadne Androulidaki; Erini Dermitzaki; Maria Venihaki; Effie Karagianni; Olga Rassouli; Erini Andreakou; Christos Stournaras; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2009-06-02       Impact factor: 27.401

6.  Blockage of heme oxygenase-1 abrogates the protective effect of regulatory T cells on murine pregnancy and promotes the maturation of dendritic cells.

Authors:  Anne Schumacher; Paul Ojiambo Wafula; Ana Teles; Tarek El-Mousleh; Nadja Linzke; Maria Laura Zenclussen; Stefanie Langwisch; Kristina Heinze; Ivonne Wollenberg; Pablo Ariel Casalis; Hans-Dieter Volk; Stefan Fest; Ana Claudia Zenclussen
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

7.  Effects of corticotrophin releasing hormone (CRH) on cell viability and differentiation in the human BeWo choriocarcinoma cell line: a potential syncytialisation inducer distinct from cyclic adenosine monophosphate (cAMP).

Authors:  YuXia Chen; Megan Allars; Xin Pan; Kaushik Maiti; Giavanna Angeli; Roger Smith; Richard C Nicholson
Journal:  Reprod Biol Endocrinol       Date:  2013-04-15       Impact factor: 5.211

8.  Differential expression of CRH, UCN, CRHR1 and CRHR2 in eutopic and ectopic endometrium of women with endometriosis.

Authors:  Aikaterini Vergetaki; Udo Jeschke; Thomas Vrekoussis; Eirini Taliouri; Luca Sabatini; Evangelia A Papakonstanti; Antonis Makrigiannakis
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.